Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,1744930,volume of distribution,"The pharmacokinetic characteristics of carprofen in healthy cows were a small volume of distribution (0.09 l/kg), a relatively low systemic clearance (2.4 ml/h kg), and a long elimination half-life (30.7 h).","Pharmacodynamics and pharmacokinetics of carprofen, a non-steroidal anti-inflammatory drug, in healthy cows and cows with Escherichia coli endotoxin-induced mastitis. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744930/),[l] / [kg],0.09,5875,DB00821,Carprofen
,1744930,systemic clearance,"The pharmacokinetic characteristics of carprofen in healthy cows were a small volume of distribution (0.09 l/kg), a relatively low systemic clearance (2.4 ml/h kg), and a long elimination half-life (30.7 h).","Pharmacodynamics and pharmacokinetics of carprofen, a non-steroidal anti-inflammatory drug, in healthy cows and cows with Escherichia coli endotoxin-induced mastitis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744930/),[ml] / [h·kg],2.4,5876,DB00821,Carprofen
,1744930,elimination half-life,"The pharmacokinetic characteristics of carprofen in healthy cows were a small volume of distribution (0.09 l/kg), a relatively low systemic clearance (2.4 ml/h kg), and a long elimination half-life (30.7 h).","Pharmacodynamics and pharmacokinetics of carprofen, a non-steroidal anti-inflammatory drug, in healthy cows and cows with Escherichia coli endotoxin-induced mastitis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744930/),h,30.7,5877,DB00821,Carprofen
,1744930,systemic clearance,"In the mastitic cows, systemic clearance (1.4 ml/h kg) was significantly lower (P less than 0.01), and elimination half-life (43.0 h) was significantly longer (P less than 0.01) than in the normal animals.","Pharmacodynamics and pharmacokinetics of carprofen, a non-steroidal anti-inflammatory drug, in healthy cows and cows with Escherichia coli endotoxin-induced mastitis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744930/),[ml] / [h·kg],1.4,5878,DB00821,Carprofen
,1744930,elimination half-life,"In the mastitic cows, systemic clearance (1.4 ml/h kg) was significantly lower (P less than 0.01), and elimination half-life (43.0 h) was significantly longer (P less than 0.01) than in the normal animals.","Pharmacodynamics and pharmacokinetics of carprofen, a non-steroidal anti-inflammatory drug, in healthy cows and cows with Escherichia coli endotoxin-induced mastitis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744930/),h,43.0,5879,DB00821,Carprofen
,32875570,Plasma Concentration,"Using the standard methodology for medication control the Irrelevant Plasma Concentration was determined as 20 and 2 ng/mL for carprofen and firocoxib, respectively.",Pharmacokinetics of carprofen and firocoxib for medication control in racing greyhounds. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32875570/),[ng] / [ml],20,30846,DB00821,Carprofen
,32875570,Plasma Concentration,"Using the standard methodology for medication control the Irrelevant Plasma Concentration was determined as 20 and 2 ng/mL for carprofen and firocoxib, respectively.",Pharmacokinetics of carprofen and firocoxib for medication control in racing greyhounds. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32875570/),[ng] / [ml],2,30847,DB00821,Carprofen
,32875570,Urine,"The Irrelevant Urine Concentration was also determined as 0.3 and 2 ng/mL for carprofen and firocoxib, respectively.",Pharmacokinetics of carprofen and firocoxib for medication control in racing greyhounds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32875570/),[ng] / [ml],0.3,30848,DB00821,Carprofen
,32875570,Urine,"The Irrelevant Urine Concentration was also determined as 0.3 and 2 ng/mL for carprofen and firocoxib, respectively.",Pharmacokinetics of carprofen and firocoxib for medication control in racing greyhounds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32875570/),[ng] / [ml],2,30849,DB00821,Carprofen
,32875570,Concentration,"The Irrelevant Urine Concentration was also determined as 0.3 and 2 ng/mL for carprofen and firocoxib, respectively.",Pharmacokinetics of carprofen and firocoxib for medication control in racing greyhounds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32875570/),[ng] / [ml],0.3,30850,DB00821,Carprofen
,32875570,Concentration,"The Irrelevant Urine Concentration was also determined as 0.3 and 2 ng/mL for carprofen and firocoxib, respectively.",Pharmacokinetics of carprofen and firocoxib for medication control in racing greyhounds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32875570/),[ng] / [ml],2,30851,DB00821,Carprofen
over,7151844,absolute bioavailability,The maximum concentration in plasma is reached after 1 hour and the absolute bioavailability of the oral forms reaches values of over 90%.,Pharmacokinetic properties of carprofen in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7151844/),%,90,42631,DB00821,Carprofen
,7151844,elimination half-life,The elimination half-life is 10 hours.,Pharmacokinetic properties of carprofen in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7151844/),h,10,42632,DB00821,Carprofen
,1915228,volume of distribution,The main pharmacokinetic characteristics of carprofen in horses and ponies were a volume of distribution of 0.08 to 0.32 litres/kg (mean +/- se = 0.23 +/- 0.04) a systemic clearance of 26.4 to 78.5 ml/min (mean +/- se = 44.9 +/- 8.0) and a plasma elimination half-life of 14.5 to 31.4 h (mean +/- se = 21.9 +/- 2.3).,"Pharmacokinetic, biochemical and tolerance studies on carprofen in the horse. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1915228/),[l] / [kg],0.08 to 0.32,47507,DB00821,Carprofen
,1915228,volume of distribution,The main pharmacokinetic characteristics of carprofen in horses and ponies were a volume of distribution of 0.08 to 0.32 litres/kg (mean +/- se = 0.23 +/- 0.04) a systemic clearance of 26.4 to 78.5 ml/min (mean +/- se = 44.9 +/- 8.0) and a plasma elimination half-life of 14.5 to 31.4 h (mean +/- se = 21.9 +/- 2.3).,"Pharmacokinetic, biochemical and tolerance studies on carprofen in the horse. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1915228/),[l] / [kg],0.23,47508,DB00821,Carprofen
,1915228,systemic clearance,The main pharmacokinetic characteristics of carprofen in horses and ponies were a volume of distribution of 0.08 to 0.32 litres/kg (mean +/- se = 0.23 +/- 0.04) a systemic clearance of 26.4 to 78.5 ml/min (mean +/- se = 44.9 +/- 8.0) and a plasma elimination half-life of 14.5 to 31.4 h (mean +/- se = 21.9 +/- 2.3).,"Pharmacokinetic, biochemical and tolerance studies on carprofen in the horse. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1915228/),[ml] / [min],26.4 to 78.5,47509,DB00821,Carprofen
,1915228,systemic clearance,The main pharmacokinetic characteristics of carprofen in horses and ponies were a volume of distribution of 0.08 to 0.32 litres/kg (mean +/- se = 0.23 +/- 0.04) a systemic clearance of 26.4 to 78.5 ml/min (mean +/- se = 44.9 +/- 8.0) and a plasma elimination half-life of 14.5 to 31.4 h (mean +/- se = 21.9 +/- 2.3).,"Pharmacokinetic, biochemical and tolerance studies on carprofen in the horse. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1915228/),[ml] / [min],44.9,47510,DB00821,Carprofen
,1915228,plasma elimination half-life,The main pharmacokinetic characteristics of carprofen in horses and ponies were a volume of distribution of 0.08 to 0.32 litres/kg (mean +/- se = 0.23 +/- 0.04) a systemic clearance of 26.4 to 78.5 ml/min (mean +/- se = 44.9 +/- 8.0) and a plasma elimination half-life of 14.5 to 31.4 h (mean +/- se = 21.9 +/- 2.3).,"Pharmacokinetic, biochemical and tolerance studies on carprofen in the horse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1915228/),h,14.5 to 31.4,47511,DB00821,Carprofen
,1915228,plasma elimination half-life,The main pharmacokinetic characteristics of carprofen in horses and ponies were a volume of distribution of 0.08 to 0.32 litres/kg (mean +/- se = 0.23 +/- 0.04) a systemic clearance of 26.4 to 78.5 ml/min (mean +/- se = 44.9 +/- 8.0) and a plasma elimination half-life of 14.5 to 31.4 h (mean +/- se = 21.9 +/- 2.3).,"Pharmacokinetic, biochemical and tolerance studies on carprofen in the horse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1915228/),h,21.9,47512,DB00821,Carprofen
,34208822,elimination half-life (t1/2λz),"The elimination half-life (t1/2λz) was 30.66, 46.11, and 41.08 h for IV, IM and oral routes, respectively.",Pharmacokinetics and Bioavailability of Carprofen in Rainbow Trout (Oncorhynchus mykiss) Broodstock. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34208822/),h,30.66,49256,DB00821,Carprofen
,34208822,elimination half-life (t1/2λz),"The elimination half-life (t1/2λz) was 30.66, 46.11, and 41.08 h for IV, IM and oral routes, respectively.",Pharmacokinetics and Bioavailability of Carprofen in Rainbow Trout (Oncorhynchus mykiss) Broodstock. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34208822/),h,46.11,49257,DB00821,Carprofen
,34208822,elimination half-life (t1/2λz),"The elimination half-life (t1/2λz) was 30.66, 46.11, and 41.08 h for IV, IM and oral routes, respectively.",Pharmacokinetics and Bioavailability of Carprofen in Rainbow Trout (Oncorhynchus mykiss) Broodstock. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34208822/),h,41.08,49258,DB00821,Carprofen
,34208822,total clearance,Carprofen for the IV route showed the total clearance of 0.02 L/h/kg and volume of distribution at steady state of 0.60 L/kg.,Pharmacokinetics and Bioavailability of Carprofen in Rainbow Trout (Oncorhynchus mykiss) Broodstock. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34208822/),[l] / [h·kg],0.02,49259,DB00821,Carprofen
,34208822,volume of distribution at steady state,Carprofen for the IV route showed the total clearance of 0.02 L/h/kg and volume of distribution at steady state of 0.60 L/kg.,Pharmacokinetics and Bioavailability of Carprofen in Rainbow Trout (Oncorhynchus mykiss) Broodstock. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34208822/),[l] / [kg],0.60,49260,DB00821,Carprofen
,34208822,peak plasma concentration (Cmax),"For IM and oral routes, the peak plasma concentration (Cmax) was 3.96 and 2.52 μg/mL with the time to reach Cmax of 2 and 4 h, respectively.",Pharmacokinetics and Bioavailability of Carprofen in Rainbow Trout (Oncorhynchus mykiss) Broodstock. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34208822/),[μg] / [ml],3.96,49261,DB00821,Carprofen
,34208822,peak plasma concentration (Cmax),"For IM and oral routes, the peak plasma concentration (Cmax) was 3.96 and 2.52 μg/mL with the time to reach Cmax of 2 and 4 h, respectively.",Pharmacokinetics and Bioavailability of Carprofen in Rainbow Trout (Oncorhynchus mykiss) Broodstock. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34208822/),[μg] / [ml],2.52,49262,DB00821,Carprofen
,34208822,time to reach Cmax,"For IM and oral routes, the peak plasma concentration (Cmax) was 3.96 and 2.52 μg/mL with the time to reach Cmax of 2 and 4 h, respectively.",Pharmacokinetics and Bioavailability of Carprofen in Rainbow Trout (Oncorhynchus mykiss) Broodstock. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34208822/),h,2,49263,DB00821,Carprofen
,34208822,time to reach Cmax,"For IM and oral routes, the peak plasma concentration (Cmax) was 3.96 and 2.52 μg/mL with the time to reach Cmax of 2 and 4 h, respectively.",Pharmacokinetics and Bioavailability of Carprofen in Rainbow Trout (Oncorhynchus mykiss) Broodstock. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34208822/),h,4,49264,DB00821,Carprofen
,34208822,bioavailability,The bioavailability was 121.89% for IM route and 78.66% for oral route.,Pharmacokinetics and Bioavailability of Carprofen in Rainbow Trout (Oncorhynchus mykiss) Broodstock. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34208822/),%,121.89,49265,DB00821,Carprofen
,34208822,bioavailability,The bioavailability was 121.89% for IM route and 78.66% for oral route.,Pharmacokinetics and Bioavailability of Carprofen in Rainbow Trout (Oncorhynchus mykiss) Broodstock. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34208822/),%,78.66,49266,DB00821,Carprofen
,22913421,area under the serum concentration-time curve (AUC0-96 h,"S(+) enantiomer means for area under the serum concentration-time curve (AUC0-96 h were 136.9 and 128.3 μg·h/mL and means for the terminal half-life (T(1/2) k10 ) were = 12.9 and 17.3 h for carprofen alone and in combination with oxytetracycline, respectively.",Influence of oxytetracycline on carprofen pharmacodynamics and pharmacokinetics in calves. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913421/),[h·μg] / [ml],136.9,52646,DB00821,Carprofen
,22913421,area under the serum concentration-time curve (AUC0-96 h,"S(+) enantiomer means for area under the serum concentration-time curve (AUC0-96 h were 136.9 and 128.3 μg·h/mL and means for the terminal half-life (T(1/2) k10 ) were = 12.9 and 17.3 h for carprofen alone and in combination with oxytetracycline, respectively.",Influence of oxytetracycline on carprofen pharmacodynamics and pharmacokinetics in calves. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913421/),[h·μg] / [ml],128.3,52647,DB00821,Carprofen
,22913421,terminal half-life (T(1/2) k10 ),"S(+) enantiomer means for area under the serum concentration-time curve (AUC0-96 h were 136.9 and 128.3 μg·h/mL and means for the terminal half-life (T(1/2) k10 ) were = 12.9 and 17.3 h for carprofen alone and in combination with oxytetracycline, respectively.",Influence of oxytetracycline on carprofen pharmacodynamics and pharmacokinetics in calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913421/),h,12.9,52648,DB00821,Carprofen
,22913421,terminal half-life (T(1/2) k10 ),"S(+) enantiomer means for area under the serum concentration-time curve (AUC0-96 h were 136.9 and 128.3 μg·h/mL and means for the terminal half-life (T(1/2) k10 ) were = 12.9 and 17.3 h for carprofen alone and in combination with oxytetracycline, respectively.",Influence of oxytetracycline on carprofen pharmacodynamics and pharmacokinetics in calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913421/),h,17.3,52649,DB00821,Carprofen
,22913421,time to achieve maximum concentrations,"Inhibition of PGE2 correlated with mean time to achieve maximum concentrations in exudate of 54 and 42 h for both carprofen treatments for R(-) and S(+) enantiomers, respectively.",Influence of oxytetracycline on carprofen pharmacodynamics and pharmacokinetics in calves. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913421/),h,54,52650,DB00821,Carprofen
,22913421,time to achieve maximum concentrations,"Inhibition of PGE2 correlated with mean time to achieve maximum concentrations in exudate of 54 and 42 h for both carprofen treatments for R(-) and S(+) enantiomers, respectively.",Influence of oxytetracycline on carprofen pharmacodynamics and pharmacokinetics in calves. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913421/),h,42,52651,DB00821,Carprofen
,2265238,elimination half-life,After intravenous applications the basic disposition parameters could be determined: mean (+/- S.D.) elimination half-life was about 11.7 (+/- 3.1) h; volume of distribution ranged from 0.12 to 0.22 l kg-1 and total plasma clearance was about 0.017 +/- 0.003 l h kg-1.,"Biopharmaceutical evaluation of carprofen following single intravenous, oral, and rectal doses in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265238/),h,11.7,55831,DB00821,Carprofen
,2265238,volume of distribution,After intravenous applications the basic disposition parameters could be determined: mean (+/- S.D.) elimination half-life was about 11.7 (+/- 3.1) h; volume of distribution ranged from 0.12 to 0.22 l kg-1 and total plasma clearance was about 0.017 +/- 0.003 l h kg-1.,"Biopharmaceutical evaluation of carprofen following single intravenous, oral, and rectal doses in dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265238/),[l] / [kg],0.12 to 0.22,55832,DB00821,Carprofen
,2265238,total plasma clearance,After intravenous applications the basic disposition parameters could be determined: mean (+/- S.D.) elimination half-life was about 11.7 (+/- 3.1) h; volume of distribution ranged from 0.12 to 0.22 l kg-1 and total plasma clearance was about 0.017 +/- 0.003 l h kg-1.,"Biopharmaceutical evaluation of carprofen following single intravenous, oral, and rectal doses in dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265238/),[h·l] / [kg],0.017,55833,DB00821,Carprofen
,2265238,time of maximum concentration,"After oral dosing, carprofen was rapidly absorbed (time of maximum concentration: 0.83 +/- 0.61 h) and comparison with the intravenous solution indicated complete bioavailability.","Biopharmaceutical evaluation of carprofen following single intravenous, oral, and rectal doses in dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265238/),h,0.83,55834,DB00821,Carprofen
,2265238,Relative bioavailabilities,Relative bioavailabilities of the drug from the suppository were about 20 per cent lower than from rectal solutions.,"Biopharmaceutical evaluation of carprofen following single intravenous, oral, and rectal doses in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265238/),%,20,55835,DB00821,Carprofen
,7082777,lag time,"After a lag time of 0.3 +/- 0.1 h (mean +/- S.D.), carprofen was absorbed rapidly and peak concentrations in the plasma were reached in 2.7 +/- 1.3 h.",The pharmacokinetics and metabolism of 14C-carprofen in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7082777/),h,0.3,64250,DB00821,Carprofen
,7082777,half-lives,"The mean half-lives of the initial (alpha) and terminal (beta) phases were 1.1 h and 20.6 +/- 6.1 h, respectively.",The pharmacokinetics and metabolism of 14C-carprofen in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7082777/),h,1.1,64251,DB00821,Carprofen
,7082777,half-lives,"The mean half-lives of the initial (alpha) and terminal (beta) phases were 1.1 h and 20.6 +/- 6.1 h, respectively.",The pharmacokinetics and metabolism of 14C-carprofen in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7082777/),h,20.6,64252,DB00821,Carprofen
,17397299,maximum concentration,"Compared with the control treatment, administration of AC decreased plasma carprofen concentrations (mean +/- SD maximum concentration was 85.9 +/- 11.9 mg/L and 58.1 +/- 17.6 mg/L, and area under the time-concentration curve was 960 +/- 233 mg/L x h and 373 +/- 133 mg/L x h after control and AC treatment, respectively).",Effects of urine alkalization and activated charcoal on the pharmacokinetics of orally administered carprofen in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17397299/),[mg] / [l],85.9,70233,DB00821,Carprofen
,17397299,maximum concentration,"Compared with the control treatment, administration of AC decreased plasma carprofen concentrations (mean +/- SD maximum concentration was 85.9 +/- 11.9 mg/L and 58.1 +/- 17.6 mg/L, and area under the time-concentration curve was 960 +/- 233 mg/L x h and 373 +/- 133 mg/L x h after control and AC treatment, respectively).",Effects of urine alkalization and activated charcoal on the pharmacokinetics of orally administered carprofen in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17397299/),[mg] / [l],58.1,70234,DB00821,Carprofen
,17397299,area under the time-concentration curve,"Compared with the control treatment, administration of AC decreased plasma carprofen concentrations (mean +/- SD maximum concentration was 85.9 +/- 11.9 mg/L and 58.1 +/- 17.6 mg/L, and area under the time-concentration curve was 960 +/- 233 mg/L x h and 373 +/- 133 mg/L x h after control and AC treatment, respectively).",Effects of urine alkalization and activated charcoal on the pharmacokinetics of orally administered carprofen in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17397299/),[mg] / [h·l],960,70235,DB00821,Carprofen
,17397299,area under the time-concentration curve,"Compared with the control treatment, administration of AC decreased plasma carprofen concentrations (mean +/- SD maximum concentration was 85.9 +/- 11.9 mg/L and 58.1 +/- 17.6 mg/L, and area under the time-concentration curve was 960 +/- 233 mg/L x h and 373 +/- 133 mg/L x h after control and AC treatment, respectively).",Effects of urine alkalization and activated charcoal on the pharmacokinetics of orally administered carprofen in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17397299/),[mg] / [h·l],373,70236,DB00821,Carprofen
,23415880,Cmax/MIC,"The CAMHB MIC data satisfied integrated PK/PD relationships predicted to achieve efficacy for approximately 48 h after dosing; mean values for serum were 5.13 (Cmax/MIC), 49.3 h (T>MIC) and 126.6 h (AUC(96h)/MIC).",Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline administered alone and in combination with carprofen in calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23415880/),,5.13,93873,DB00821,Carprofen
,23415880,T>MIC,"The CAMHB MIC data satisfied integrated PK/PD relationships predicted to achieve efficacy for approximately 48 h after dosing; mean values for serum were 5.13 (Cmax/MIC), 49.3 h (T>MIC) and 126.6 h (AUC(96h)/MIC).",Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline administered alone and in combination with carprofen in calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23415880/),h,49.3,93874,DB00821,Carprofen
,23415880,AUC(96h)/MIC,"The CAMHB MIC data satisfied integrated PK/PD relationships predicted to achieve efficacy for approximately 48 h after dosing; mean values for serum were 5.13 (Cmax/MIC), 49.3 h (T>MIC) and 126.6 h (AUC(96h)/MIC).",Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline administered alone and in combination with carprofen in calves. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23415880/),h,126.6,93875,DB00821,Carprofen
,23415880,Cmax/MIC,"However, PK-PD integration of data, based on oxytetracycline MICs determined in the biological fluids, serum, exudate and transudate, suggest that it possesses, at most, limited direct killing activity against the M. haemolytica strain A1 76/1; mean values for serum were 0.277 (Cmax/MIC), 0 h (T>MIC) and 6.84 h (AUC(96h)/MIC).",Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline administered alone and in combination with carprofen in calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23415880/),,0.277,93876,DB00821,Carprofen
,23415880,T>MIC,"However, PK-PD integration of data, based on oxytetracycline MICs determined in the biological fluids, serum, exudate and transudate, suggest that it possesses, at most, limited direct killing activity against the M. haemolytica strain A1 76/1; mean values for serum were 0.277 (Cmax/MIC), 0 h (T>MIC) and 6.84 h (AUC(96h)/MIC).",Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline administered alone and in combination with carprofen in calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23415880/),h,0,93877,DB00821,Carprofen
,23415880,AUC(96h)/MIC,"However, PK-PD integration of data, based on oxytetracycline MICs determined in the biological fluids, serum, exudate and transudate, suggest that it possesses, at most, limited direct killing activity against the M. haemolytica strain A1 76/1; mean values for serum were 0.277 (Cmax/MIC), 0 h (T>MIC) and 6.84 h (AUC(96h)/MIC).",Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline administered alone and in combination with carprofen in calves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23415880/),h,6.84,93878,DB00821,Carprofen
,10849251,elimination half-life (t1/2),"Early and extended sample time points suggest that the pharmacokinetics of carprofen in the cat fit a 2-compartment model, with a long elimination half-life (t1/2) of 20.1 +/- 16.6 h, an area under the plasma concentration-time curve (AUC) of 637 (+/- 237) microgram.",The pharmacokinetics and effects of intravenously administered carprofen and salicylate on gastrointestinal mucosa and selected biochemical measurements in healthy cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849251/),h,20.1,94701,DB00821,Carprofen
,10849251,area under the plasma concentration-time curve (AUC),"Early and extended sample time points suggest that the pharmacokinetics of carprofen in the cat fit a 2-compartment model, with a long elimination half-life (t1/2) of 20.1 +/- 16.6 h, an area under the plasma concentration-time curve (AUC) of 637 (+/- 237) microgram.",The pharmacokinetics and effects of intravenously administered carprofen and salicylate on gastrointestinal mucosa and selected biochemical measurements in healthy cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849251/),μg,637,94702,DB00821,Carprofen
,10849251,volume of distribution (Vdss),mL/h and a volume of distribution (Vdss) of 0.14 +/- 0.05 L/kg.,The pharmacokinetics and effects of intravenously administered carprofen and salicylate on gastrointestinal mucosa and selected biochemical measurements in healthy cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849251/),[l] / [kg],0.14,94703,DB00821,Carprofen
,10849251,elimination half-life (t1/2),"Intravenously administered aspirin fit a 2-compartment model and had a long elimination half-life (t1/2) of 22.2 +/- 3.1 h, an AUC of 3824.2 +/- 506.7 microgram.",The pharmacokinetics and effects of intravenously administered carprofen and salicylate on gastrointestinal mucosa and selected biochemical measurements in healthy cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849251/),h,22.2,94704,DB00821,Carprofen
,10849251,AUC,"Intravenously administered aspirin fit a 2-compartment model and had a long elimination half-life (t1/2) of 22.2 +/- 3.1 h, an AUC of 3824.2 +/- 506.7 microgram.",The pharmacokinetics and effects of intravenously administered carprofen and salicylate on gastrointestinal mucosa and selected biochemical measurements in healthy cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849251/),μg,3824.2,94705,DB00821,Carprofen
,10849251,volume of distribution (Vdss),mL/h and a volume of distribution (Vdss) of 0.17 +/- 0. 01 L/kg.,The pharmacokinetics and effects of intravenously administered carprofen and salicylate on gastrointestinal mucosa and selected biochemical measurements in healthy cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849251/),[l] / [kg],0.17,94706,DB00821,Carprofen
,29691872,half-life of λz,"The half-life of λz and mean residence time was 105.71 ± 15.67 and 155.01 ± 22.46 hr, respectively.",A study of the pharmacokinetics and thromboxane inhibitory activity of a single intramuscular dose of carprofen as a means to establish its potential use as an analgesic drug in white rhinoceros. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29691872/),h,105.71,99372,DB00821,Carprofen
,29691872,mean residence time,"The half-life of λz and mean residence time was 105.71 ± 15.67 and 155.01 ± 22.46 hr, respectively.",A study of the pharmacokinetics and thromboxane inhibitory activity of a single intramuscular dose of carprofen as a means to establish its potential use as an analgesic drug in white rhinoceros. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29691872/),h,155.01,99373,DB00821,Carprofen
,29691872,area under the curve,"The area under the curve and the maximum carprofen concentration were 904.61 ± 110.78 μg ml-1 hr-1 and 5.77 ± 0.63 μg/ml, respectively.",A study of the pharmacokinetics and thromboxane inhibitory activity of a single intramuscular dose of carprofen as a means to establish its potential use as an analgesic drug in white rhinoceros. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29691872/),[μg] / [h·ml],904.61,99374,DB00821,Carprofen
,29691872,maximum carprofen concentration,"The area under the curve and the maximum carprofen concentration were 904.61 ± 110.78 μg ml-1 hr-1 and 5.77 ± 0.63 μg/ml, respectively.",A study of the pharmacokinetics and thromboxane inhibitory activity of a single intramuscular dose of carprofen as a means to establish its potential use as an analgesic drug in white rhinoceros. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29691872/),[μg] / [ml],5.77,99375,DB00821,Carprofen
,8542839,elimination half-life,"Following intravenous administration of 0.7 mg racemic carprofen/kg bwt, mean values for pharmacokinetic parameters were 18.1 h (elimination half-life); 0.25 l/kg (volume of distribution, Vd[area]); 58.9 ml/min (clearance); and 57.9 micrograms/ml.h (area under plasma concentration time curve).",Pharmacodynamics and pharmacokinetics of carprofen in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8542839/),h,18.1,101824,DB00821,Carprofen
,8542839,"volume of distribution, Vd[area]","Following intravenous administration of 0.7 mg racemic carprofen/kg bwt, mean values for pharmacokinetic parameters were 18.1 h (elimination half-life); 0.25 l/kg (volume of distribution, Vd[area]); 58.9 ml/min (clearance); and 57.9 micrograms/ml.h (area under plasma concentration time curve).",Pharmacodynamics and pharmacokinetics of carprofen in the horse. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8542839/),[l] / [kg],0.25,101825,DB00821,Carprofen
,8542839,clearance,"Following intravenous administration of 0.7 mg racemic carprofen/kg bwt, mean values for pharmacokinetic parameters were 18.1 h (elimination half-life); 0.25 l/kg (volume of distribution, Vd[area]); 58.9 ml/min (clearance); and 57.9 micrograms/ml.h (area under plasma concentration time curve).",Pharmacodynamics and pharmacokinetics of carprofen in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8542839/),[ml] / [min],58.9,101826,DB00821,Carprofen
,8542839,area under plasma concentration time curve,"Following intravenous administration of 0.7 mg racemic carprofen/kg bwt, mean values for pharmacokinetic parameters were 18.1 h (elimination half-life); 0.25 l/kg (volume of distribution, Vd[area]); 58.9 ml/min (clearance); and 57.9 micrograms/ml.h (area under plasma concentration time curve).",Pharmacodynamics and pharmacokinetics of carprofen in the horse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8542839/),[μg] / [h·ml],57.9,101827,DB00821,Carprofen
exceeded,8542839,exudate:plasma concentration ratios,Mean exudate:plasma concentration ratios exceeded 1.0 at all sampling times between 2 and 48 h.,Pharmacodynamics and pharmacokinetics of carprofen in the horse. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8542839/),,1.0,101828,DB00821,Carprofen
,7707490,Cmax,"Higher plasma concentrations of the (-)(R) (Cmax 18 micrograms/ml, AUC0-24 118 micrograms h/ml) than the (+)(S) (Cmax 14 micrograms/ml, AUC0-24 67 micrograms h/ml) enantiomer were achieved following administration of the racemate.",Stereospecific pharmacodynamics and pharmacokinetics of carprofen in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7707490/),[μg] / [ml],18,107520,DB00821,Carprofen
,7707490,AUC0-24,"Higher plasma concentrations of the (-)(R) (Cmax 18 micrograms/ml, AUC0-24 118 micrograms h/ml) than the (+)(S) (Cmax 14 micrograms/ml, AUC0-24 67 micrograms h/ml) enantiomer were achieved following administration of the racemate.",Stereospecific pharmacodynamics and pharmacokinetics of carprofen in the dog. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7707490/),[h·μg] / [ml],118,107521,DB00821,Carprofen
,7707490,Cmax,"Higher plasma concentrations of the (-)(R) (Cmax 18 micrograms/ml, AUC0-24 118 micrograms h/ml) than the (+)(S) (Cmax 14 micrograms/ml, AUC0-24 67 micrograms h/ml) enantiomer were achieved following administration of the racemate.",Stereospecific pharmacodynamics and pharmacokinetics of carprofen in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7707490/),[μg] / [ml],14,107522,DB00821,Carprofen
,7707490,AUC0-24,"Higher plasma concentrations of the (-)(R) (Cmax 18 micrograms/ml, AUC0-24 118 micrograms h/ml) than the (+)(S) (Cmax 14 micrograms/ml, AUC0-24 67 micrograms h/ml) enantiomer were achieved following administration of the racemate.",Stereospecific pharmacodynamics and pharmacokinetics of carprofen in the dog. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7707490/),[h·μg] / [ml],67,107523,DB00821,Carprofen
,28985539,drug,Toxicokinetic analysis revealed a prolonged drug half-life of 37.75 h in the dead bird as opposed to 13.99 ± 5.61 h from healthy birds dosed intravenously at 5 mg/kg.,The use of toxicokinetics and exposure studies to show that carprofen in cattle tissue could lead to secondary toxicity and death in wild vultures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28985539/),h,37.75,111364,DB00821,Carprofen
,28985539,half-life,Toxicokinetic analysis revealed a prolonged drug half-life of 37.75 h in the dead bird as opposed to 13.99 ± 5.61 h from healthy birds dosed intravenously at 5 mg/kg.,The use of toxicokinetics and exposure studies to show that carprofen in cattle tissue could lead to secondary toxicity and death in wild vultures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28985539/),h,37.75,111365,DB00821,Carprofen
,28985539,half-life,Toxicokinetic analysis revealed a prolonged drug half-life of 37.75 h in the dead bird as opposed to 13.99 ± 5.61 h from healthy birds dosed intravenously at 5 mg/kg.,The use of toxicokinetics and exposure studies to show that carprofen in cattle tissue could lead to secondary toxicity and death in wild vultures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28985539/),h,13.99,111366,DB00821,Carprofen
,33303396,initial plasma concentration,The initial plasma concentration of IV carprofen was estimated at 54.57 ± 3.92 μg mL-1 and decreased to 8.26 ± 1.07 μg mL-1 24 hours later.,Pharmacokinetics of carprofen in anaesthetized pigs: a preliminary study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33303396/),[μg] / [ml],54.57,117443,DB00821,Carprofen
,33303396,initial plasma concentration,The initial plasma concentration of IV carprofen was estimated at 54.57 ± 3.92 μg mL-1 and decreased to 8.26 ± 1.07 μg mL-1 24 hours later.,Pharmacokinetics of carprofen in anaesthetized pigs: a preliminary study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33303396/),[μg] / [ml],8.26,117444,DB00821,Carprofen
,33303396,distribution half-life,The plasma elimination curve showed a bi-exponential decline: a rapid distribution phase with a distribution half-life of 0.21 ± 0.03 hours and a slower elimination phase with an elimination half-life of 17.31 ± 3.78 hours.,Pharmacokinetics of carprofen in anaesthetized pigs: a preliminary study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33303396/),h,0.21,117445,DB00821,Carprofen
,33303396,elimination half-life,The plasma elimination curve showed a bi-exponential decline: a rapid distribution phase with a distribution half-life of 0.21 ± 0.03 hours and a slower elimination phase with an elimination half-life of 17.31 ± 3.78 hours.,Pharmacokinetics of carprofen in anaesthetized pigs: a preliminary study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33303396/),h,17.31,117446,DB00821,Carprofen
,33303396,area under the plasma concentration-time curve,"The calculated pharmacokinetic parameters were as follows: the area under the plasma concentration-time curve was 357.3 ± 16.73 μg mL-1 hour, volume of distribution was 0.28 ± 0.07 L kg-1 and plasma clearance rate was 0.19 ± 0.009 mL minute-1 kg-1.",Pharmacokinetics of carprofen in anaesthetized pigs: a preliminary study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33303396/),[h·μg] / [ml],357.3,117447,DB00821,Carprofen
,33303396,volume of distribution,"The calculated pharmacokinetic parameters were as follows: the area under the plasma concentration-time curve was 357.3 ± 16.73 μg mL-1 hour, volume of distribution was 0.28 ± 0.07 L kg-1 and plasma clearance rate was 0.19 ± 0.009 mL minute-1 kg-1.",Pharmacokinetics of carprofen in anaesthetized pigs: a preliminary study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33303396/),[l] / [kg],0.28,117448,DB00821,Carprofen
,33303396,plasma clearance rate,"The calculated pharmacokinetic parameters were as follows: the area under the plasma concentration-time curve was 357.3 ± 16.73 μg mL-1 hour, volume of distribution was 0.28 ± 0.07 L kg-1 and plasma clearance rate was 0.19 ± 0.009 mL minute-1 kg-1.",Pharmacokinetics of carprofen in anaesthetized pigs: a preliminary study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33303396/),[ml] / [kg·min],0.19,117449,DB00821,Carprofen
,3886707,area under plasma concentration-time curve,"The mean +/- SD area under plasma concentration-time curve and apparent oral plasma clearance values were 57.8 +/- 11.7 micrograms X h/mL and 30.0 +/- 6.3 mL/min, respectively, in patients and 52.4 +/- 11.3 micrograms X h/mL and 33.1 +/- 7.2 mL/min in normals.",The influence of liver dysfunction on the pharmacokinetics of carprofen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3886707/),[h·μg] / [ml],57.8,123571,DB00821,Carprofen
,3886707,area under plasma concentration-time curve,"The mean +/- SD area under plasma concentration-time curve and apparent oral plasma clearance values were 57.8 +/- 11.7 micrograms X h/mL and 30.0 +/- 6.3 mL/min, respectively, in patients and 52.4 +/- 11.3 micrograms X h/mL and 33.1 +/- 7.2 mL/min in normals.",The influence of liver dysfunction on the pharmacokinetics of carprofen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3886707/),[h·μg] / [ml],52.4,123572,DB00821,Carprofen
,3886707,apparent oral plasma clearance,"The mean +/- SD area under plasma concentration-time curve and apparent oral plasma clearance values were 57.8 +/- 11.7 micrograms X h/mL and 30.0 +/- 6.3 mL/min, respectively, in patients and 52.4 +/- 11.3 micrograms X h/mL and 33.1 +/- 7.2 mL/min in normals.",The influence of liver dysfunction on the pharmacokinetics of carprofen. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3886707/),[ml] / [min],30.0,123573,DB00821,Carprofen
,3886707,apparent oral plasma clearance,"The mean +/- SD area under plasma concentration-time curve and apparent oral plasma clearance values were 57.8 +/- 11.7 micrograms X h/mL and 30.0 +/- 6.3 mL/min, respectively, in patients and 52.4 +/- 11.3 micrograms X h/mL and 33.1 +/- 7.2 mL/min in normals.",The influence of liver dysfunction on the pharmacokinetics of carprofen. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3886707/),[ml] / [min],33.1,123574,DB00821,Carprofen
,3886707,elimination half-lives,The respective harmonic mean elimination half-lives were 10.5 and 9.4 hours.,The influence of liver dysfunction on the pharmacokinetics of carprofen. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3886707/),h,10.5,123575,DB00821,Carprofen
,3886707,elimination half-lives,The respective harmonic mean elimination half-lives were 10.5 and 9.4 hours.,The influence of liver dysfunction on the pharmacokinetics of carprofen. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3886707/),h,9.4,123576,DB00821,Carprofen
,3886707,0-24 hour,"The 0-24 hour urinary recovery of intact drug and the glucuronide conjugate were 7.0 +/- 4.9% and 28.9 +/- 11.0%, respectively, in patients compared to 5.5 +/- 7.1% and 20.1 +/- 12.3% in normal subjects.",The influence of liver dysfunction on the pharmacokinetics of carprofen. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3886707/),%,7.0,123577,DB00821,Carprofen
,3886707,0-24 hour,"The 0-24 hour urinary recovery of intact drug and the glucuronide conjugate were 7.0 +/- 4.9% and 28.9 +/- 11.0%, respectively, in patients compared to 5.5 +/- 7.1% and 20.1 +/- 12.3% in normal subjects.",The influence of liver dysfunction on the pharmacokinetics of carprofen. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3886707/),%,5.5,123578,DB00821,Carprofen
,3886707,0-24 hour,"The 0-24 hour urinary recovery of intact drug and the glucuronide conjugate were 7.0 +/- 4.9% and 28.9 +/- 11.0%, respectively, in patients compared to 5.5 +/- 7.1% and 20.1 +/- 12.3% in normal subjects.",The influence of liver dysfunction on the pharmacokinetics of carprofen. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3886707/),%,20.1,123579,DB00821,Carprofen
,3886707,urinary recovery,"The 0-24 hour urinary recovery of intact drug and the glucuronide conjugate were 7.0 +/- 4.9% and 28.9 +/- 11.0%, respectively, in patients compared to 5.5 +/- 7.1% and 20.1 +/- 12.3% in normal subjects.",The influence of liver dysfunction on the pharmacokinetics of carprofen. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3886707/),%,7.0,123580,DB00821,Carprofen
,3886707,urinary recovery,"The 0-24 hour urinary recovery of intact drug and the glucuronide conjugate were 7.0 +/- 4.9% and 28.9 +/- 11.0%, respectively, in patients compared to 5.5 +/- 7.1% and 20.1 +/- 12.3% in normal subjects.",The influence of liver dysfunction on the pharmacokinetics of carprofen. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3886707/),%,28.9,123581,DB00821,Carprofen
,3886707,urinary recovery,"The 0-24 hour urinary recovery of intact drug and the glucuronide conjugate were 7.0 +/- 4.9% and 28.9 +/- 11.0%, respectively, in patients compared to 5.5 +/- 7.1% and 20.1 +/- 12.3% in normal subjects.",The influence of liver dysfunction on the pharmacokinetics of carprofen. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3886707/),%,5.5,123582,DB00821,Carprofen
,3886707,urinary recovery,"The 0-24 hour urinary recovery of intact drug and the glucuronide conjugate were 7.0 +/- 4.9% and 28.9 +/- 11.0%, respectively, in patients compared to 5.5 +/- 7.1% and 20.1 +/- 12.3% in normal subjects.",The influence of liver dysfunction on the pharmacokinetics of carprofen. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3886707/),%,20.1,123583,DB00821,Carprofen
less,3552584,Volume of distribution,Volume of distribution is mostly low (less than 0.2 L/kg) and protein binding is high (usually 95 to 99%).,Non-steroidal anti-inflammatory analgesics other than salicylates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),[l] / [kg],0.2,136228,DB00821,Carprofen
,3552584,elimination half-life,"The elimination half-life of the arylalkanoic acid derivatives is in most instances about 2 to 5 hours, although notable exceptions include carprofen (approximately equal to 20 h), fenbufen (10 h), naproxen (12-15 h) and sulindac (16 h for the active metabolite).",Non-steroidal anti-inflammatory analgesics other than salicylates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,2 to 5,136229,DB00821,Carprofen
,3552584,elimination half-life,"The elimination half-life of the arylalkanoic acid derivatives is in most instances about 2 to 5 hours, although notable exceptions include carprofen (approximately equal to 20 h), fenbufen (10 h), naproxen (12-15 h) and sulindac (16 h for the active metabolite).",Non-steroidal anti-inflammatory analgesics other than salicylates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,20,136230,DB00821,Carprofen
,3552584,elimination half-life,"The elimination half-life of the arylalkanoic acid derivatives is in most instances about 2 to 5 hours, although notable exceptions include carprofen (approximately equal to 20 h), fenbufen (10 h), naproxen (12-15 h) and sulindac (16 h for the active metabolite).",Non-steroidal anti-inflammatory analgesics other than salicylates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,10,136231,DB00821,Carprofen
,3552584,elimination half-life,"The elimination half-life of the arylalkanoic acid derivatives is in most instances about 2 to 5 hours, although notable exceptions include carprofen (approximately equal to 20 h), fenbufen (10 h), naproxen (12-15 h) and sulindac (16 h for the active metabolite).",Non-steroidal anti-inflammatory analgesics other than salicylates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,12-15,136232,DB00821,Carprofen
,3552584,elimination half-life,"The elimination half-life of the arylalkanoic acid derivatives is in most instances about 2 to 5 hours, although notable exceptions include carprofen (approximately equal to 20 h), fenbufen (10 h), naproxen (12-15 h) and sulindac (16 h for the active metabolite).",Non-steroidal anti-inflammatory analgesics other than salicylates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,16,136233,DB00821,Carprofen
,3552584,half-life,"Piroxicam has the longest half-life, averaging 45 hours.",Non-steroidal anti-inflammatory analgesics other than salicylates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3552584/),h,45,136234,DB00821,Carprofen
,33846990,Vdarea /F,"The Vdarea /F of MLX, CRP, and TA after IM administration was 0.28, 2.05, and 0.20 L/kg.","Pharmacokinetics of meloxicam, carprofen, and tolfenamic acid after intramuscular and oral administration in Japanese quails (Coturnix coturnix japonica). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33846990/),[l] / [kg],0.28,150315,DB00821,Carprofen
,33846990,Vdarea /F,"The Vdarea /F of MLX, CRP, and TA after IM administration was 0.28, 2.05, and 0.20 L/kg.","Pharmacokinetics of meloxicam, carprofen, and tolfenamic acid after intramuscular and oral administration in Japanese quails (Coturnix coturnix japonica). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33846990/),[l] / [kg],2.05,150316,DB00821,Carprofen
,33846990,Vdarea /F,"The Vdarea /F of MLX, CRP, and TA after IM administration was 0.28, 2.05, and 0.20 L/kg.","Pharmacokinetics of meloxicam, carprofen, and tolfenamic acid after intramuscular and oral administration in Japanese quails (Coturnix coturnix japonica). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33846990/),[l] / [kg],0.20,150317,DB00821,Carprofen
,33846990,Cl/F,"The Cl/F of MLX, CRP, and TA after IM administration was 0.12, 0.19, and 0.09 L/h/kg.","Pharmacokinetics of meloxicam, carprofen, and tolfenamic acid after intramuscular and oral administration in Japanese quails (Coturnix coturnix japonica). ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33846990/),[l] / [h·kg],0.12,150318,DB00821,Carprofen
,33846990,Cl/F,"The Cl/F of MLX, CRP, and TA after IM administration was 0.12, 0.19, and 0.09 L/h/kg.","Pharmacokinetics of meloxicam, carprofen, and tolfenamic acid after intramuscular and oral administration in Japanese quails (Coturnix coturnix japonica). ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33846990/),[l] / [h·kg],0.19,150319,DB00821,Carprofen
,33846990,Cl/F,"The Cl/F of MLX, CRP, and TA after IM administration was 0.12, 0.19, and 0.09 L/h/kg.","Pharmacokinetics of meloxicam, carprofen, and tolfenamic acid after intramuscular and oral administration in Japanese quails (Coturnix coturnix japonica). ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33846990/),[l] / [h·kg],0.09,150320,DB00821,Carprofen
,33846990,relative bioavailability,"The relative bioavailability of MLX, CRP, and TA following oral administration in quails was 76.13%, 61.46%, and 57.32%, respectively.","Pharmacokinetics of meloxicam, carprofen, and tolfenamic acid after intramuscular and oral administration in Japanese quails (Coturnix coturnix japonica). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33846990/),%,76.13,150321,DB00821,Carprofen
,33846990,relative bioavailability,"The relative bioavailability of MLX, CRP, and TA following oral administration in quails was 76.13%, 61.46%, and 57.32%, respectively.","Pharmacokinetics of meloxicam, carprofen, and tolfenamic acid after intramuscular and oral administration in Japanese quails (Coturnix coturnix japonica). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33846990/),%,61.46,150322,DB00821,Carprofen
,33846990,relative bioavailability,"The relative bioavailability of MLX, CRP, and TA following oral administration in quails was 76.13%, 61.46%, and 57.32%, respectively.","Pharmacokinetics of meloxicam, carprofen, and tolfenamic acid after intramuscular and oral administration in Japanese quails (Coturnix coturnix japonica). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33846990/),%,57.32,150323,DB00821,Carprofen
,20004922,IC(50,"The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88).",In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004922/),,128.8,153272,DB00821,Carprofen
,20004922,IC(50,"The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88).",In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004922/),,48.5,153273,DB00821,Carprofen
,20004922,IC(50,"The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88).",In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004922/),,29.2,153274,DB00821,Carprofen
,20004922,IC(50,"The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88).",In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004922/),,17.,153275,DB00821,Carprofen
,20004922,IC(50,"The rank order of selectivity for inhibition of COX-2 versus COX-1 (IC(50) COX-1:IC(50) COX-2) for veterinary drugs was highest with robenacoxib (128.8) compared to deracoxib (48.5), nimesulide (29.2), S+ carprofen (17.6), meloxicam (7.3), etodolac (6.6), R- carprofen (5.8) and ketoprofen (0.88).",In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20004922/),,7,153276,DB00821,Carprofen
,2352151,partition coefficient,"The influence of the hydrophilicity of fatty suppository bases on the rectal absorption of the lipophilic drug carprofen (octanol-buffer, pH 7.4; partition coefficient, 40) was investigated in dogs.","Influence of the hydrophilicity of suppository bases on rectal absorption of carprofen, a lipophilic nonsteroidal anti-inflammatory drug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2352151/),,40,157969,DB00821,Carprofen
,2352151,hydroxyl,"The suppository vehicles tested were semisynthetic glycerides containing saturated fatty acids mainly in the range of C10 to C18 [Massa Estarinum A (MEA), Massa Estarinum B (MEB), and Massa Estarinum 299 (ME299)]; their hydroxyl values increased from 1 for ME299, through 24 for MEB, to 45 for MEA.","Influence of the hydrophilicity of suppository bases on rectal absorption of carprofen, a lipophilic nonsteroidal anti-inflammatory drug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2352151/),,1,157970,DB00821,Carprofen
,2352151,hydroxyl,"The suppository vehicles tested were semisynthetic glycerides containing saturated fatty acids mainly in the range of C10 to C18 [Massa Estarinum A (MEA), Massa Estarinum B (MEB), and Massa Estarinum 299 (ME299)]; their hydroxyl values increased from 1 for ME299, through 24 for MEB, to 45 for MEA.","Influence of the hydrophilicity of suppository bases on rectal absorption of carprofen, a lipophilic nonsteroidal anti-inflammatory drug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2352151/),,24,157971,DB00821,Carprofen
,2352151,hydroxyl,"The suppository vehicles tested were semisynthetic glycerides containing saturated fatty acids mainly in the range of C10 to C18 [Massa Estarinum A (MEA), Massa Estarinum B (MEB), and Massa Estarinum 299 (ME299)]; their hydroxyl values increased from 1 for ME299, through 24 for MEB, to 45 for MEA.","Influence of the hydrophilicity of suppository bases on rectal absorption of carprofen, a lipophilic nonsteroidal anti-inflammatory drug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2352151/),,45,157972,DB00821,Carprofen
,2352151,mean absorption times (MAT),"After rectal administration of suppositories, the rate and extent of carprofen absorption increased with the hydroxyl value of the suppository base; the mean absorption times (MAT) and tmax were shorter with MEA (2.15 and 1.7 h, respectively) than with the less hydrophilic vehicles (MEB: 4.09 and 2.1 h, respectively; ME299: 4.22 and 2.4 h, respectively).","Influence of the hydrophilicity of suppository bases on rectal absorption of carprofen, a lipophilic nonsteroidal anti-inflammatory drug. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2352151/),h,2.15,157973,DB00821,Carprofen
,2352151,mean absorption times (MAT),"After rectal administration of suppositories, the rate and extent of carprofen absorption increased with the hydroxyl value of the suppository base; the mean absorption times (MAT) and tmax were shorter with MEA (2.15 and 1.7 h, respectively) than with the less hydrophilic vehicles (MEB: 4.09 and 2.1 h, respectively; ME299: 4.22 and 2.4 h, respectively).","Influence of the hydrophilicity of suppository bases on rectal absorption of carprofen, a lipophilic nonsteroidal anti-inflammatory drug. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2352151/),h,4.09,157974,DB00821,Carprofen
,2352151,mean absorption times (MAT),"After rectal administration of suppositories, the rate and extent of carprofen absorption increased with the hydroxyl value of the suppository base; the mean absorption times (MAT) and tmax were shorter with MEA (2.15 and 1.7 h, respectively) than with the less hydrophilic vehicles (MEB: 4.09 and 2.1 h, respectively; ME299: 4.22 and 2.4 h, respectively).","Influence of the hydrophilicity of suppository bases on rectal absorption of carprofen, a lipophilic nonsteroidal anti-inflammatory drug. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2352151/),h,2.1,157975,DB00821,Carprofen
,2352151,mean absorption times (MAT),"After rectal administration of suppositories, the rate and extent of carprofen absorption increased with the hydroxyl value of the suppository base; the mean absorption times (MAT) and tmax were shorter with MEA (2.15 and 1.7 h, respectively) than with the less hydrophilic vehicles (MEB: 4.09 and 2.1 h, respectively; ME299: 4.22 and 2.4 h, respectively).","Influence of the hydrophilicity of suppository bases on rectal absorption of carprofen, a lipophilic nonsteroidal anti-inflammatory drug. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2352151/),,4.22,157976,DB00821,Carprofen
,2352151,mean absorption times (MAT),"After rectal administration of suppositories, the rate and extent of carprofen absorption increased with the hydroxyl value of the suppository base; the mean absorption times (MAT) and tmax were shorter with MEA (2.15 and 1.7 h, respectively) than with the less hydrophilic vehicles (MEB: 4.09 and 2.1 h, respectively; ME299: 4.22 and 2.4 h, respectively).","Influence of the hydrophilicity of suppository bases on rectal absorption of carprofen, a lipophilic nonsteroidal anti-inflammatory drug. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2352151/),h,2.4,157977,DB00821,Carprofen
,2352151,tmax,"After rectal administration of suppositories, the rate and extent of carprofen absorption increased with the hydroxyl value of the suppository base; the mean absorption times (MAT) and tmax were shorter with MEA (2.15 and 1.7 h, respectively) than with the less hydrophilic vehicles (MEB: 4.09 and 2.1 h, respectively; ME299: 4.22 and 2.4 h, respectively).","Influence of the hydrophilicity of suppository bases on rectal absorption of carprofen, a lipophilic nonsteroidal anti-inflammatory drug. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2352151/),h,1.7,157978,DB00821,Carprofen
,2352151,tmax,"After rectal administration of suppositories, the rate and extent of carprofen absorption increased with the hydroxyl value of the suppository base; the mean absorption times (MAT) and tmax were shorter with MEA (2.15 and 1.7 h, respectively) than with the less hydrophilic vehicles (MEB: 4.09 and 2.1 h, respectively; ME299: 4.22 and 2.4 h, respectively).","Influence of the hydrophilicity of suppository bases on rectal absorption of carprofen, a lipophilic nonsteroidal anti-inflammatory drug. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2352151/),h,2.4,157979,DB00821,Carprofen
,12485349,plasma,"R(-)-carprofen was the predominant enantiomer in all three fluids, as indicated by plasma area under the curve (AUC) values for R(-) and S(+)-carprofen of 117.4 and 22.6 microg h/mL (low dose carprofen) and 557.5 and 138.1 microg h/mL (high dose carprofen) respectively.",Pharmacodynamics and enantioselective pharmacokinetics of racemic carprofen in the horse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485349/),[h·μg] / [ml],117.4,165587,DB00821,Carprofen
,12485349,plasma,"R(-)-carprofen was the predominant enantiomer in all three fluids, as indicated by plasma area under the curve (AUC) values for R(-) and S(+)-carprofen of 117.4 and 22.6 microg h/mL (low dose carprofen) and 557.5 and 138.1 microg h/mL (high dose carprofen) respectively.",Pharmacodynamics and enantioselective pharmacokinetics of racemic carprofen in the horse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485349/),[h·μg] / [ml],557.5,165588,DB00821,Carprofen
,12485349,area under the curve (AUC),"R(-)-carprofen was the predominant enantiomer in all three fluids, as indicated by plasma area under the curve (AUC) values for R(-) and S(+)-carprofen of 117.4 and 22.6 microg h/mL (low dose carprofen) and 557.5 and 138.1 microg h/mL (high dose carprofen) respectively.",Pharmacodynamics and enantioselective pharmacokinetics of racemic carprofen in the horse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485349/),[h·μg] / [ml],117.4,165589,DB00821,Carprofen
,12485349,area under the curve (AUC),"R(-)-carprofen was the predominant enantiomer in all three fluids, as indicated by plasma area under the curve (AUC) values for R(-) and S(+)-carprofen of 117.4 and 22.6 microg h/mL (low dose carprofen) and 557.5 and 138.1 microg h/mL (high dose carprofen) respectively.",Pharmacodynamics and enantioselective pharmacokinetics of racemic carprofen in the horse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485349/),[h·μg] / [ml],22.6,165590,DB00821,Carprofen
,12485349,area under the curve (AUC),"R(-)-carprofen was the predominant enantiomer in all three fluids, as indicated by plasma area under the curve (AUC) values for R(-) and S(+)-carprofen of 117.4 and 22.6 microg h/mL (low dose carprofen) and 557.5 and 138.1 microg h/mL (high dose carprofen) respectively.",Pharmacodynamics and enantioselective pharmacokinetics of racemic carprofen in the horse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485349/),[h·μg] / [ml],557.5,165591,DB00821,Carprofen
,12485349,area under the curve (AUC),"R(-)-carprofen was the predominant enantiomer in all three fluids, as indicated by plasma area under the curve (AUC) values for R(-) and S(+)-carprofen of 117.4 and 22.6 microg h/mL (low dose carprofen) and 557.5 and 138.1 microg h/mL (high dose carprofen) respectively.",Pharmacodynamics and enantioselective pharmacokinetics of racemic carprofen in the horse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485349/),[h·μg] / [ml],138.1,165592,DB00821,Carprofen
,2928755,plasma elimination half-life,The plasma elimination half-life of carprofen ranged from 44.5 to 64.6 h after repeated daily injections.,"Carprofen in veterinary medicine. I. Plasma disposition, milk excretion and tolerance in milk-producing cows. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2928755/),h,44.5 to 64.6,186982,DB00821,Carprofen
,2928755,volume of distribution,The volume of distribution and the clearance values calculated after a single intravenous injection amounted to 0.09 l/kg and 9.0 ml/min.,"Carprofen in veterinary medicine. I. Plasma disposition, milk excretion and tolerance in milk-producing cows. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2928755/),[l] / [kg],0.09,186983,DB00821,Carprofen
,2928755,clearance,The volume of distribution and the clearance values calculated after a single intravenous injection amounted to 0.09 l/kg and 9.0 ml/min.,"Carprofen in veterinary medicine. I. Plasma disposition, milk excretion and tolerance in milk-producing cows. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2928755/),[ml] / [min],9.0,186984,DB00821,Carprofen
,7400372,t 1/2,"After a single dose of 100 mg, plasma caprofen peaked in 1 to 2 hours, and t 1/2 was estimated to be 4.4 +/- 1.4 hours, based on a monoexponential fit of the data.",Pharmacokinetic and clinical studies of carprofen in gout. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7400372/),h,4.4,188947,DB00821,Carprofen
,7452450,half-life,"In the three human subjects studied, the terminal component declined with a 13--26 hr half-life; the terminal half-life was approximately 40 hr in dogs.","Metabolism of carprofen, a nonsteroid anti-inflammatory agent, in rats, dogs, and humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452450/),h,13--26,189691,DB00821,Carprofen
,7452450,terminal half-life,"In the three human subjects studied, the terminal component declined with a 13--26 hr half-life; the terminal half-life was approximately 40 hr in dogs.","Metabolism of carprofen, a nonsteroid anti-inflammatory agent, in rats, dogs, and humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452450/),h,40,189692,DB00821,Carprofen
,32448336,clearance,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [h·kg],1.29,200615,DB00821,Carprofen
,32448336,clearance,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [h·kg],1.65,200616,DB00821,Carprofen
,32448336,clearance,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [h·kg],1.40,200617,DB00821,Carprofen
,32448336,volume of distribution,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [kg],6.8,200618,DB00821,Carprofen
,32448336,volume of distribution,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [kg],14.2,200619,DB00821,Carprofen
,32448336,volume of distribution,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [kg],40.1,200620,DB00821,Carprofen
,32448336,elimination half-life,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),h,3.7,200621,DB00821,Carprofen
,32448336,elimination half-life,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),h,5.7,200622,DB00821,Carprofen
,32448336,elimination half-life,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),h,22,200623,DB00821,Carprofen
,32448336,area under the plasma concentration-time curved extrapolated to infinity,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[ng] / [h·ml],15.7,200624,DB00821,Carprofen
,32448336,area under the plasma concentration-time curved extrapolated to infinity,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[ng] / [h·ml],12.4,200625,DB00821,Carprofen
,32448336,area under the plasma concentration-time curved extrapolated to infinity,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[ng] / [h·ml],16.4,200626,DB00821,Carprofen
,32448336,Bioavailability,"Bioavailability for IM and SC was 62.6 and 40%, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),%,62.6,200627,DB00821,Carprofen
,32448336,Bioavailability,"Bioavailability for IM and SC was 62.6 and 40%, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),%,40,200628,DB00821,Carprofen
,32448336,Maximum plasma concentrations,"Maximum plasma concentrations of buprenorphine were 6.2 and 1.3 ng/mL at 0.14 and 0.33 h after IM and SC administration, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[ng] / [ml],6.2,200629,DB00821,Carprofen
,32448336,Maximum plasma concentrations,"Maximum plasma concentrations of buprenorphine were 6.2 and 1.3 ng/mL at 0.14 and 0.33 h after IM and SC administration, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[ng] / [ml],1.3,200630,DB00821,Carprofen
,28416162,Maximum concentration,"Maximum concentration was 23.92 ± 8.64 ng mL-1 at 1 minute (maximum time); elimination half-life was 41.87 ± 17.35 minutes; area under the curve was 486.68 ± 125.66 minutes ng-1 mL-1; clearance was 33.61 ± 13.01 mL minute-1 kg-1, and volume of distribution at steady state was 1.77 ± 0.50 L kg-1.",Pharmacokinetics of buprenorphine following constant rate infusion for postoperative analgesia in dogs undergoing ovariectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28416162/),[ng] / [ml],23.92,204605,DB00821,Carprofen
,28416162,elimination half-life,"Maximum concentration was 23.92 ± 8.64 ng mL-1 at 1 minute (maximum time); elimination half-life was 41.87 ± 17.35 minutes; area under the curve was 486.68 ± 125.66 minutes ng-1 mL-1; clearance was 33.61 ± 13.01 mL minute-1 kg-1, and volume of distribution at steady state was 1.77 ± 0.50 L kg-1.",Pharmacokinetics of buprenorphine following constant rate infusion for postoperative analgesia in dogs undergoing ovariectomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28416162/),min,41.87,204606,DB00821,Carprofen
,28416162,area under the curve,"Maximum concentration was 23.92 ± 8.64 ng mL-1 at 1 minute (maximum time); elimination half-life was 41.87 ± 17.35 minutes; area under the curve was 486.68 ± 125.66 minutes ng-1 mL-1; clearance was 33.61 ± 13.01 mL minute-1 kg-1, and volume of distribution at steady state was 1.77 ± 0.50 L kg-1.",Pharmacokinetics of buprenorphine following constant rate infusion for postoperative analgesia in dogs undergoing ovariectomy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28416162/),[min] / [ml·ng],486.68,204607,DB00821,Carprofen
,28416162,clearance,"Maximum concentration was 23.92 ± 8.64 ng mL-1 at 1 minute (maximum time); elimination half-life was 41.87 ± 17.35 minutes; area under the curve was 486.68 ± 125.66 minutes ng-1 mL-1; clearance was 33.61 ± 13.01 mL minute-1 kg-1, and volume of distribution at steady state was 1.77 ± 0.50 L kg-1.",Pharmacokinetics of buprenorphine following constant rate infusion for postoperative analgesia in dogs undergoing ovariectomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28416162/),[ml] / [kg·min],33.61,204608,DB00821,Carprofen
,28416162,volume of distribution at steady state,"Maximum concentration was 23.92 ± 8.64 ng mL-1 at 1 minute (maximum time); elimination half-life was 41.87 ± 17.35 minutes; area under the curve was 486.68 ± 125.66 minutes ng-1 mL-1; clearance was 33.61 ± 13.01 mL minute-1 kg-1, and volume of distribution at steady state was 1.77 ± 0.50 L kg-1.",Pharmacokinetics of buprenorphine following constant rate infusion for postoperative analgesia in dogs undergoing ovariectomy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28416162/),[l] / [kg],1.77,204609,DB00821,Carprofen
,15077695,selectivity ratio,"Blood concentrations that resulted in 50% inhibition of COX-1 and COX-2 activity in vitro were 119.1 microM and 0.31 microM, respectively, and selectivity ratio for inhibiting COX-2 relative to COX-1 was 384.",In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15077695/),,384,213432,DB00821,Carprofen
,15077695,oral bioavailability,"ML-1,785,713 had high oral bioavailability (101%), low systemic clearance (77 mL/min/kg), and an elimination half-life of 5.9 hours.",In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15077695/),%,101,213433,DB00821,Carprofen
,15077695,systemic clearance,"ML-1,785,713 had high oral bioavailability (101%), low systemic clearance (77 mL/min/kg), and an elimination half-life of 5.9 hours.",In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15077695/),[ml] / [kg·min],77,213434,DB00821,Carprofen
,15077695,elimination half-life,"ML-1,785,713 had high oral bioavailability (101%), low systemic clearance (77 mL/min/kg), and an elimination half-life of 5.9 hours.",In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15077695/),h,5.9,213435,DB00821,Carprofen
,1686227,inversion ratio,The (R)- to (S)-enantiomer inversion ratio for flunoxaprofen in rats was 0.54.,"Stereoselective disposition of carprofen, flunoxaprofen, and naproxen in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686227/),,0.54,217457,DB00821,Carprofen
,24041210,peak meloxicam,"Plasma analyzed by HPLC (meloxicam) and tandem mass spectrometry (carprofen) revealed that the peak meloxicam and carprofen concentrations were 16.7 and 20.3 μg/mL and occurred at 4 and 2 h after oral gavage, respectively.",Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041210/),[μg] / [ml],16.7,219752,DB00821,Carprofen
,24041210,peak meloxicam,"Plasma analyzed by HPLC (meloxicam) and tandem mass spectrometry (carprofen) revealed that the peak meloxicam and carprofen concentrations were 16.7 and 20.3 μg/mL and occurred at 4 and 2 h after oral gavage, respectively.",Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041210/),[μg] / [ml],20.3,219753,DB00821,Carprofen
,24041210,concentrations,"Plasma analyzed by HPLC (meloxicam) and tandem mass spectrometry (carprofen) revealed that the peak meloxicam and carprofen concentrations were 16.7 and 20.3 μg/mL and occurred at 4 and 2 h after oral gavage, respectively.",Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041210/),[μg] / [ml],16.7,219754,DB00821,Carprofen
,24041210,concentrations,"Plasma analyzed by HPLC (meloxicam) and tandem mass spectrometry (carprofen) revealed that the peak meloxicam and carprofen concentrations were 16.7 and 20.3 μg/mL and occurred at 4 and 2 h after oral gavage, respectively.",Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041210/),[μg] / [ml],20.3,219755,DB00821,Carprofen
,24041210,plasma AUC,"Meloxicam plasma AUC, elimination half-life, apparent volume of distribution, and apparent oral clearance were 160.4 mg/L × h, 7.4 h, 0.36 L/kg, and 0.125 mL/h × kg, respectively.",Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041210/),[mg] / [h·l],160.4,219756,DB00821,Carprofen
,24041210,elimination half-life,"Meloxicam plasma AUC, elimination half-life, apparent volume of distribution, and apparent oral clearance were 160.4 mg/L × h, 7.4 h, 0.36 L/kg, and 0.125 mL/h × kg, respectively.",Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041210/),h,7.4,219757,DB00821,Carprofen
,24041210,apparent volume of distribution,"Meloxicam plasma AUC, elimination half-life, apparent volume of distribution, and apparent oral clearance were 160.4 mg/L × h, 7.4 h, 0.36 L/kg, and 0.125 mL/h × kg, respectively.",Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041210/),h,7.4,219758,DB00821,Carprofen
,24041210,apparent volume of distribution,"Meloxicam plasma AUC, elimination half-life, apparent volume of distribution, and apparent oral clearance were 160.4 mg/L × h, 7.4 h, 0.36 L/kg, and 0.125 mL/h × kg, respectively.",Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041210/),[l] / [kg],0.36,219759,DB00821,Carprofen
,24041210,apparent oral clearance,"Meloxicam plasma AUC, elimination half-life, apparent volume of distribution, and apparent oral clearance were 160.4 mg/L × h, 7.4 h, 0.36 L/kg, and 0.125 mL/h × kg, respectively.",Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041210/),[ml] / [h·kg],0.125,219760,DB00821,Carprofen
,24041210,plasma AUC,"Carprofen plasma AUC, elimination half-life, apparent volume of distribution, and apparent oral clearance were 160.8 mg/L × h, 7.4 h, 0.42 L/kg, and 0.062 mL/h × kg, respectively.",Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041210/),[mg] / [h·l],160.8,219761,DB00821,Carprofen
,24041210,elimination half-life,"Carprofen plasma AUC, elimination half-life, apparent volume of distribution, and apparent oral clearance were 160.8 mg/L × h, 7.4 h, 0.42 L/kg, and 0.062 mL/h × kg, respectively.",Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041210/),h,7.4,219762,DB00821,Carprofen
,24041210,apparent volume of distribution,"Carprofen plasma AUC, elimination half-life, apparent volume of distribution, and apparent oral clearance were 160.8 mg/L × h, 7.4 h, 0.42 L/kg, and 0.062 mL/h × kg, respectively.",Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041210/),h,7.4,219763,DB00821,Carprofen
,24041210,apparent volume of distribution,"Carprofen plasma AUC, elimination half-life, apparent volume of distribution, and apparent oral clearance were 160.8 mg/L × h, 7.4 h, 0.42 L/kg, and 0.062 mL/h × kg, respectively.",Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041210/),[l] / [kg],0.42,219764,DB00821,Carprofen
,24041210,apparent oral clearance,"Carprofen plasma AUC, elimination half-life, apparent volume of distribution, and apparent oral clearance were 160.8 mg/L × h, 7.4 h, 0.42 L/kg, and 0.062 mL/h × kg, respectively.",Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24041210/),[ml] / [h·kg],0.062,219765,DB00821,Carprofen
,8685536,bioavailability,"The main features of carprofen pharmacokinetics were a low distribution volume, a relatively long elimination half-life, the predominance of the R(-) enantiomer and a bioavailability (after subcutaneous dosing) of 100 per cent and 92 per cent, respectively, after doses of 0.7 and 4.0 mg kg-1.",Pharmacodynamics and enantioselective pharmacokinetics of carprofen in the cat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685536/),%,100,223360,DB00821,Carprofen
,8685536,bioavailability,"The main features of carprofen pharmacokinetics were a low distribution volume, a relatively long elimination half-life, the predominance of the R(-) enantiomer and a bioavailability (after subcutaneous dosing) of 100 per cent and 92 per cent, respectively, after doses of 0.7 and 4.0 mg kg-1.",Pharmacodynamics and enantioselective pharmacokinetics of carprofen in the cat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685536/),%,92,223361,DB00821,Carprofen
,19000261,observed clearance,Mean observed clearance of R(-)-CPF (82.17 +/- 13.70 mL/h.kg) was more rapid than for S(+)-CPF (27.92 +/- 7.07 mL/h.kg; P < 0.001).,Enantioselective pharmacokinetics of racemic carprofen in New Zealand white rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000261/),[ml] / [h·kg],82.17,244542,DB00821,Carprofen
,19000261,observed clearance,Mean observed clearance of R(-)-CPF (82.17 +/- 13.70 mL/h.kg) was more rapid than for S(+)-CPF (27.92 +/- 7.07 mL/h.kg; P < 0.001).,Enantioselective pharmacokinetics of racemic carprofen in New Zealand white rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000261/),[ml] / [h·kg],27.92,244543,DB00821,Carprofen
,19000261,T(1/2)lambda z,"T(1/2)lambda z was shorter for R(-)-CPF than S(+)-CPF after both i.v. (1.03 and 2.99 h, respectively) and s.c. (1.94 and 4.14 h, respectively) dosing.",Enantioselective pharmacokinetics of racemic carprofen in New Zealand white rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000261/),h,1.03,244544,DB00821,Carprofen
,19000261,T(1/2)lambda z,"T(1/2)lambda z was shorter for R(-)-CPF than S(+)-CPF after both i.v. (1.03 and 2.99 h, respectively) and s.c. (1.94 and 4.14 h, respectively) dosing.",Enantioselective pharmacokinetics of racemic carprofen in New Zealand white rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000261/),h,2.99,244545,DB00821,Carprofen
,19000261,T(1/2)lambda z,"T(1/2)lambda z was shorter for R(-)-CPF than S(+)-CPF after both i.v. (1.03 and 2.99 h, respectively) and s.c. (1.94 and 4.14 h, respectively) dosing.",Enantioselective pharmacokinetics of racemic carprofen in New Zealand white rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000261/),h,1.94,244546,DB00821,Carprofen
,19000261,T(1/2)lambda z,"T(1/2)lambda z was shorter for R(-)-CPF than S(+)-CPF after both i.v. (1.03 and 2.99 h, respectively) and s.c. (1.94 and 4.14 h, respectively) dosing.",Enantioselective pharmacokinetics of racemic carprofen in New Zealand white rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000261/),h,4.14,244547,DB00821,Carprofen
,19000261,AUC(0-->infinity) ratios,Mean AUC(0-->infinity) ratios for R(-):S(+)-CPF were approximately 1:3 for both routes of administration.,Enantioselective pharmacokinetics of racemic carprofen in New Zealand white rabbits. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000261/),,1:3,244548,DB00821,Carprofen
,19000261,Mean residence time,"Mean residence time of R(-)-CPF was shorter than of S(+)-CPF (1.06 +/- 0.29 h, 3.45 +/- 0.50 h; P < 0.001) and R(-)- and S(+)-CPF volumes of distribution at steady state were 85.00 +/- 14.42 and 94.39 +/- 18.66 mL/kg, respectively after i.v. administration.",Enantioselective pharmacokinetics of racemic carprofen in New Zealand white rabbits. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000261/),h,1.06,244549,DB00821,Carprofen
,19000261,Mean residence time,"Mean residence time of R(-)-CPF was shorter than of S(+)-CPF (1.06 +/- 0.29 h, 3.45 +/- 0.50 h; P < 0.001) and R(-)- and S(+)-CPF volumes of distribution at steady state were 85.00 +/- 14.42 and 94.39 +/- 18.66 mL/kg, respectively after i.v. administration.",Enantioselective pharmacokinetics of racemic carprofen in New Zealand white rabbits. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000261/),h,3.45,244550,DB00821,Carprofen
,19000261,volumes of distribution at steady state,"Mean residence time of R(-)-CPF was shorter than of S(+)-CPF (1.06 +/- 0.29 h, 3.45 +/- 0.50 h; P < 0.001) and R(-)- and S(+)-CPF volumes of distribution at steady state were 85.00 +/- 14.42 and 94.39 +/- 18.66 mL/kg, respectively after i.v. administration.",Enantioselective pharmacokinetics of racemic carprofen in New Zealand white rabbits. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000261/),[ml] / [kg],85.00,244551,DB00821,Carprofen
,19000261,volumes of distribution at steady state,"Mean residence time of R(-)-CPF was shorter than of S(+)-CPF (1.06 +/- 0.29 h, 3.45 +/- 0.50 h; P < 0.001) and R(-)- and S(+)-CPF volumes of distribution at steady state were 85.00 +/- 14.42 and 94.39 +/- 18.66 mL/kg, respectively after i.v. administration.",Enantioselective pharmacokinetics of racemic carprofen in New Zealand white rabbits. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000261/),[ml] / [kg],94.39,244552,DB00821,Carprofen
,19000261,bioavailability [F (%)],"The mean s.c. bioavailability [F (%)] for both R(-)- and S(+)-CPF was high, 94.4 +/- 22.8 and 91.0 +/- 35.7%, respectively.",Enantioselective pharmacokinetics of racemic carprofen in New Zealand white rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000261/),%,94.4,244553,DB00821,Carprofen
,19000261,bioavailability [F (%)],"The mean s.c. bioavailability [F (%)] for both R(-)- and S(+)-CPF was high, 94.4 +/- 22.8 and 91.0 +/- 35.7%, respectively.",Enantioselective pharmacokinetics of racemic carprofen in New Zealand white rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19000261/),%,91.0,244554,DB00821,Carprofen
,8364755,S(+)/R(-) ratio,"The S(+)/R(-) ratio of the ""areas under the curves"" during the time course of the kinetics, is: 0.60 in dogs, 0.53 in Yucatan micro-pigs, 0.48 in mini-goats, 0.67 in calves and 0.19 in horses.","[Comparative enantioselectivity of the disposition of two non-steroidal anti-inflammatory agents, ketoprofen and carprofen, in man and animals]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364755/),,0.60,254562,DB00821,Carprofen
,8364755,S(+)/R(-) ratio,"The S(+)/R(-) ratio of the ""areas under the curves"" during the time course of the kinetics, is: 0.60 in dogs, 0.53 in Yucatan micro-pigs, 0.48 in mini-goats, 0.67 in calves and 0.19 in horses.","[Comparative enantioselectivity of the disposition of two non-steroidal anti-inflammatory agents, ketoprofen and carprofen, in man and animals]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364755/),,0.53,254563,DB00821,Carprofen
,8364755,S(+)/R(-) ratio,"The S(+)/R(-) ratio of the ""areas under the curves"" during the time course of the kinetics, is: 0.60 in dogs, 0.53 in Yucatan micro-pigs, 0.48 in mini-goats, 0.67 in calves and 0.19 in horses.","[Comparative enantioselectivity of the disposition of two non-steroidal anti-inflammatory agents, ketoprofen and carprofen, in man and animals]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364755/),,0.48,254564,DB00821,Carprofen
,8364755,S(+)/R(-) ratio,"The S(+)/R(-) ratio of the ""areas under the curves"" during the time course of the kinetics, is: 0.60 in dogs, 0.53 in Yucatan micro-pigs, 0.48 in mini-goats, 0.67 in calves and 0.19 in horses.","[Comparative enantioselectivity of the disposition of two non-steroidal anti-inflammatory agents, ketoprofen and carprofen, in man and animals]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8364755/),,0,254565,DB00821,Carprofen
,26512724,maximum plasma concentration (Cmax),"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),[ng] / [ml],1051.8,256545,DB00821,Carprofen
,26512724,maximum plasma concentration (Cmax),"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),[ng] / [ml],335.9,256546,DB00821,Carprofen
,26512724,maximum plasma concentration (Cmax),"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),[ng] / [ml],11150,256547,DB00821,Carprofen
,26512724,maximum plasma concentration (Cmax),"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),h,4,256548,DB00821,Carprofen
,26512724,Tmax,"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),h,5.3,256549,DB00821,Carprofen
,26512724,half-life of elimination,"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),h,13.3,256550,DB00821,Carprofen
,26512724,half-life of elimination,"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),h,1.8,256551,DB00821,Carprofen
,26512724,half-life of elimination,"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),h,18.7,256552,DB00821,Carprofen
,12755902,Cmax,The mean Cmax and AUC0--12 were 16.9 microg/mL and 73.1 microg.,The steady-state pharmacokinetics and bioequivalence of carprofen administered orally and subcutaneously in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12755902/),[μg] / [ml],16.9,261958,DB00821,Carprofen
,12755902,AUC0--12,The mean Cmax and AUC0--12 were 16.9 microg/mL and 73.1 microg.,The steady-state pharmacokinetics and bioequivalence of carprofen administered orally and subcutaneously in dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12755902/),μg,73.1,261959,DB00821,Carprofen
,12755902,Cmax,"At steady-state, the mean Cmax and AUC0--12 were 18.7 microg/mL and 101.9 microg x h/mL, respectively, following p.o. administration and 14.7 microg/mL and 111.0 microg x h/mL, respectively, following s.c. injection.",The steady-state pharmacokinetics and bioequivalence of carprofen administered orally and subcutaneously in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12755902/),[μg] / [ml],18.7,261960,DB00821,Carprofen
,12755902,Cmax,"At steady-state, the mean Cmax and AUC0--12 were 18.7 microg/mL and 101.9 microg x h/mL, respectively, following p.o. administration and 14.7 microg/mL and 111.0 microg x h/mL, respectively, following s.c. injection.",The steady-state pharmacokinetics and bioequivalence of carprofen administered orally and subcutaneously in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12755902/),[μg] / [ml],14.7,261961,DB00821,Carprofen
,12755902,AUC0--12,"At steady-state, the mean Cmax and AUC0--12 were 18.7 microg/mL and 101.9 microg x h/mL, respectively, following p.o. administration and 14.7 microg/mL and 111.0 microg x h/mL, respectively, following s.c. injection.",The steady-state pharmacokinetics and bioequivalence of carprofen administered orally and subcutaneously in dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12755902/),[h·μg] / [ml],101.9,261962,DB00821,Carprofen
,12755902,AUC0--12,"At steady-state, the mean Cmax and AUC0--12 were 18.7 microg/mL and 101.9 microg x h/mL, respectively, following p.o. administration and 14.7 microg/mL and 111.0 microg x h/mL, respectively, following s.c. injection.",The steady-state pharmacokinetics and bioequivalence of carprofen administered orally and subcutaneously in dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12755902/),[h·μg] / [ml],111.0,261963,DB00821,Carprofen
,2571482,limit of detection,"When 0.1 ml of sample was used, the limit of detection for carprofen glucuronides was 50 ng/ml in plasma and 200 ng/ml in urine.",Direct determination of diastereomeric carprofen glucuronides in human plasma and urine and preliminary measurements of stereoselective metabolic and renal elimination after oral administration of carprofen in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571482/),[ng] / [ml],50,265218,DB00821,Carprofen
,2571482,limit of detection,"When 0.1 ml of sample was used, the limit of detection for carprofen glucuronides was 50 ng/ml in plasma and 200 ng/ml in urine.",Direct determination of diastereomeric carprofen glucuronides in human plasma and urine and preliminary measurements of stereoselective metabolic and renal elimination after oral administration of carprofen in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571482/),[ng] / [ml],200,265219,DB00821,Carprofen
,1439219,volume of distribution (Vd[area],"Carprofen had a small volume of distribution (Vd[area], 95.5 and 118.4 ml kg-1), a prolonged elimination half-life (t1/2 beta, 26.1 and 33.7 hours) and a slow body clearance rate (Clb, 2.5 ml kg-1 h-1) in sheep.",Pharmacokinetics of carprofen administered intravenously to sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1439219/),[ml] / [kg],95.5,274259,DB00821,Carprofen
,1439219,volume of distribution (Vd[area],"Carprofen had a small volume of distribution (Vd[area], 95.5 and 118.4 ml kg-1), a prolonged elimination half-life (t1/2 beta, 26.1 and 33.7 hours) and a slow body clearance rate (Clb, 2.5 ml kg-1 h-1) in sheep.",Pharmacokinetics of carprofen administered intravenously to sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1439219/),[ml] / [kg],118.4,274260,DB00821,Carprofen
,1439219,elimination half-life (t1/2 beta,"Carprofen had a small volume of distribution (Vd[area], 95.5 and 118.4 ml kg-1), a prolonged elimination half-life (t1/2 beta, 26.1 and 33.7 hours) and a slow body clearance rate (Clb, 2.5 ml kg-1 h-1) in sheep.",Pharmacokinetics of carprofen administered intravenously to sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1439219/),h,26.1,274261,DB00821,Carprofen
,1439219,elimination half-life (t1/2 beta,"Carprofen had a small volume of distribution (Vd[area], 95.5 and 118.4 ml kg-1), a prolonged elimination half-life (t1/2 beta, 26.1 and 33.7 hours) and a slow body clearance rate (Clb, 2.5 ml kg-1 h-1) in sheep.",Pharmacokinetics of carprofen administered intravenously to sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1439219/),h,33.7,274262,DB00821,Carprofen
,1439219,body clearance rate (Clb,"Carprofen had a small volume of distribution (Vd[area], 95.5 and 118.4 ml kg-1), a prolonged elimination half-life (t1/2 beta, 26.1 and 33.7 hours) and a slow body clearance rate (Clb, 2.5 ml kg-1 h-1) in sheep.",Pharmacokinetics of carprofen administered intravenously to sheep. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1439219/),[ml] / [h·kg],2.5,274263,DB00821,Carprofen
